Glutathione S-transferase and glutathione peroxidase are essential in the early stage of Adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cells

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 1, 1996, Pages 45-51

  Lee, Wei Ping ^a   Lee, Chao Lin ^a   Lin, Hui Ching ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

GPX; GSH; GST; MDR; P glycoprotein

Indexed keywords

DOXORUBICIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME ASSAY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LYMPHOMA CELL; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; BASE SEQUENCE; BLOTTING, NORTHERN; CELL DIVISION; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HUMANS; LYMPHOMA; MOLECULAR SEQUENCE DATA; P-GLYCOPROTEIN; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0029967575     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050446     Document Type: Article

References (57)

1. Bachur NR, Gordon SL, Gee MV (1977) Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 13:901-910
2. Sinha BK, Mimnaugh KG (1990) Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radical Biol Med 8: 567-581
3. Sinha BK, Trush MA, Kennedy KA, Mimnaugh KG (1984) Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res 44:2892-2896
4. Berlin V, Haseltine WA (1981) Reduction of adriamycin to a semiquinone free radical by NADPH-cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. J Biol Chem 256:4747-4756
5. Mimnaugh EG, Trush MA, Gram TH (1981) Stimulation of adriamycin of rat heart and liver microsomal NADPH dependent liver peroxidation. Biochem Pharmucol 30:2747-2804
6. Mimnaugh EG, Trush MA, Bhatnagar M, Gram TE (1984) Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug, adriamycin. Biochem Pharmacol 34:847-856
7. Tritton TR, Yee G (1982) The anticancer agent adriamycin can be actively cytotoxic without entering the cells. Science 217:248-250
8. Arrick BA, Nathan CF (1984) Glutathione metabolism as a determinant of therapeutic efficiency: a review. Cancer Res 44:4224-4232
9. Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711-760
10. Begleiter A, Leith MK, McClarty G, Beenken S, Goldenberg GJ, Wright JA (1988) Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents. Cancer Res 48:1727-1735
11. Chao CC-K, Huang Y-T, Ma CM, Chou WY, Lin-Chao S (1991) Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Mol Pharmacol 41:69-75
12. Lai GM, Moscow JA, Alvarez MG, Fojo AT, Bates SE (1991) Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines. Int J Cancer 49: 688-695
13. Deffie A M, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD, Goldenberg GJ (1988) Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin- sensitive and -resistant P388 leukemia. Cancer Res 48:3595-3602
14. Hoban PR, Robson CN, Davies SM, Hall AG, Cattan AR, Hickson ID, Harris AE (1992) Reduced topoisomerase II and elevated α class glutathione S-transferase expression in a multi-drug resistant CHO cell line highly cross-resistant to mitomycin C. Biochem Pharmacol 43:685-693
15. Chasseaud LF (1979) The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv Cancer Res 29:175-273.
16. Sinha BK, Mimnaugh EG, Rajagopalan S, Myers CE (1989) Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 49:3844-3848
17. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171
18. Fojo AT, Ariyama SI, Gottesman M M, Pastan I (1985) Reduced drug accumulation in multiply drug-resistant human K B carcinoma cell lines. Cancer Res 45:3002-3007
19. Rivera-Fillat MP, Pallares-Trujillo J, Domenech C, Grau-Oliete MR (1988) Comparative uptake, retention and action of vincristine, vinblastine and vindesine on murine leukaemic lymphoblasts sensitive and resistant to vincristine. Br J Pharmacol 93:902-908
20. Cornwell MM, Pastan I, Gottesman MM (1987) Certain calcium channel blockers bind specifically to multidrug-resistant human K B carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262:2166-2170
21. Beck WT, Cirtain MC, Thomas Look A, Ashmun RA (1986) Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil. Cancer Res 46:778-784
22. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1982) Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonist and calmodulin inhibitors. Cancer Res 42:4730-4733
23. Gros P, Neriah YB, Croop JM, Housman DF (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323:728-731
24. Lincke CR, Bliek AM van der, Schuurhuis GJ, Velde-Koerts T van der, Smit JJM, Borst P (1990) Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr 1 complementary DNA. Cancer Res 50:1779-1785
25. Baas F, Jongsma APM, Broxterman HJ, Arceci RJ, Housman D, Scheffer GL, Riethorst A, Groenigen M van, Nieuwint AWM, Joenje H (1990) Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res 50:5392-5398
26. Cole SPC, Chanda ER, Dicke FP, Gerlach JH, Mirski SEL (1991) Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51:3345-3352
27. Versantvoort CHM, Broxterman HJ, Pinedo HM, Vries EGE de, Feller N, Kuiper CM, Lankelma J (1992) Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res 52:17-23
28. Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM (1989) Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res 49:4542-4549
29. Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L, Stewart BW (1989) Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein. Cancer Res 49:5281-5287
30. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant lung cancer cell line. Science 258:1650-1654
31. Center MS, Krishnamachary N (1993) The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 53:3658-3661
32. Schneider E, Horton JK, Yang C-H, Nakagawa M, Cowan KH (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54:152-158
33. Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375
34. De Jone S, Zijstra JG, Vries EGE de, Mulder NH (1990) Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50:304-309
35. Nakagawa K, Saijo N, Tsuchida S, Sakai M, Tsunokawa Y, Yokota J, Muramatsu M, Sato K, Terada M, Tew KD (1990) Glutathione S-transferase π as a determinant of drug resistance in transfectant cell lines. J Biol Chem 265:4296-4301
36. Akman SA, Forrest G, Chu F-F, Esworthy RS, Doroshow JH (1990) Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. Cancer Res 50:1397-1402
37. Samuels BL, Murray JL, Cohen MB, Safa AR, Sinha BK, Townsend AJ, Beckett MA, Weichselbaum RR (1991) Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res 51:521-527
38. Benchekroun MN, Pourquire P, Schott B, Robert J (1993) Doxorubicin-induced lipid peroxidation and glutathione activity in tumor cell lines selected for resistance to doxorubicin. Eur J Biochem 211:141-146
39. Lee W-P, Lee C-L, Kao M-C (1992) Multidrug-resistant HOB1 lymphoma cells express P-glycoprotein that does not play the major role in the development of drug resistance to adriamycin. Biochem Biophys Res Commun 189:92-100
40. Ho Y-S, Sheu L-F, Ng J-A, Hsu S-M (1990) Establishment and characterization of an Epstein-Barr virus negative B immunoblastic lymphoma cell line. Br J Cancer 61:655-658
41. Peper RJ, Tina WZ, Mickelson MM (1968) Purification of lymphocytes and platelets by gradient centrifugation. J Lab Clin Methods 72:842-848
42. Kano T, Sakai M, Muramatsu M (1987) Structure and expression of a human class π glutathione S-transferase. Cancer Res 47:5626-5630
43. Sukenaga Y, Ishida K, Takeda T, Takagi K (1987) cDNA sequence coding for human glutathione peroxidase. Nucleic Acids Res 17:7178
44. Feinberg AP, Vogelstein B (1983) A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6-13
45. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
46. Habig WH, Pabst MJ, Jakoby WB (1974) Glutathione S-transferase. The first enzymatic step in mercapturic acid formation. J Biol Chem 249:7130-7139
47. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
48. Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glulathione peroxidase. J Lab Clin Med 70:158-169
49. Suzukake K, Petro BJ, Vistica DT (1982) Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem Pharmacol 31:121-124
50. Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 25:192-205
51. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
52. Russo A, Mitchell JB (1985) Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione metabolism. Cancer Treat Rep 69:1293-1296
53. Coleman CN, Bump EA, Kramer RA (1988) Chemical modifier of cancer therapy. J Clin Oncol 6:709-733
54. Griffith RC, Janney CG (1990) Hematopoietic system: bone marrow and blood, spleen, and lymph nodes. In: Kissane JM (ed) Anderson's pathology, 7th edn. C.V. Mosby St. Louis, pp 1373-1492
55. Chabner BA, Myers CE (1989) Clinical pharmacology of cancer chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer, principles and practice of oncology, J.B. Lippincort, Philadelphia, pp 376-380
56. Cowan KH, Batist G, Tulpule A, Sinha BK, Myers CE (1986) Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 83:9328-9332
57. Muindi JRF, Sinha BK, Gianni Z, Myers CT (1984) Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. FEBS Lett 172:226-230